heteroclitic


Also found in: Dictionary, Legal, Encyclopedia, Wikipedia.

heteroclitic

/het·ero·clit·ic/ (-klit´ik) irregular; said of a kind of antibody (see under antibody ).

heteroclitic

adjective Referring to an immune response in which antibodies cross-react with an extensive palette of antigens.
References in periodicals archive ?
So, I retrospectively searched the "ontogeny" of heteroclitic antibody or heteroclitic, and noticed that the term originally "heterclitic" has been widely used with time especially in cancer immunology field, such as heteroclitic epitopes, heteroclitic peptides or heteroclitic immunization.
It is interesting that apparently one autoantibody could be induced by a variety of mechanisms: such as by metabolic modification of auto antigens or by auto antigenun-related viral double helical RNA that could induce heteroclitic or heterospecific antibodies as mentioned above.
INNO-305, also known as WT1 heteroclitic peptide immunotherapy, is in a Phase I clinical trial for the treatment of patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) as well as patients with non-small cell lung cancer (NSCLC) and mesothelioma.
Abstract # 903: "Pilot Study of a Wilms Tumor Protein (WT1) Heteroclitic Peptide Vaccine in Patients with Myeloid and Thoracic Neoplasms.
INNO-305, also known as WT1 heteroclitic peptide immunotherapy, is in a Phase I clinical trial for the treatment of patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) as well as patients with non-small cell lung cancer (NSCLC) and mesothelioma.
INNO-305, also known as WT1 heteroclitic peptide immunotherapy, stimulates certain T-cells more efficiently than normal protein fragments, thereby activating the immune system in a more robust fashion.
NEW YORK -- Vaccine is First WT1 Heteroclitic Peptide Immunotherapeutic to Specifically Target CD4 and CD8 Activation
a biopharmaceutical company headquartered in Manhattan, announced today that it has licensed worldwide development rights for a WT1 heteroclitic peptide immunotherapeutic from Memorial Sloan-Kettering Cancer Center in New York.